Zydus Wellness Q4 FY26 Results: Key numbers to track

What investors are waiting for

Zydus Wellness (NSE: ZYDWEL) is preparing to announce its Q4 FY26 (January to March 2026) financial results for the period ended March 31, 2026. The company’s board of directors is expected to meet in May 2026 to approve the audited consolidated and standalone financial results for both the quarter and the full year.

Along with the results, the board is also expected to consider a recommendation for a final dividend. For investors tracking the stock, the results announcement will be an important near-term event because it may clarify how demand, pricing, and cost trends played out at the end of FY26.

Expected timeline and board agenda

The Zydus Wellness Q4 FY26 results date is May 2026 (expected), based on the provided information. The stated agenda is to approve audited consolidated and standalone results for the quarter and financial year ended March 31, 2026.

A final dividend recommendation is also on the table. Dividend decisions typically draw investor attention because they indicate how management is balancing shareholder returns with internal cash needs, especially after a full-year audit.

Analyst consensus: revenue, PAT, and margin expectations

Analyst consensus estimates for Q4 FY26 indicate revenue in the range of ₹620 to ₹680 crore, and profit after tax (PAT) in the range of ₹68 to ₹85 crore. Margin expectations are pegged at EBITDA of 16% to 18%.

The estimate range suggests analysts are looking for a quarter where profitability remains resilient, but the spread in projections shows uncertainty around execution and cost variables. For most consumer companies, quarter-end marketing spends, commodity costs, and distribution intensity can shape EBITDA outcomes.

Brokerage previews and how Q3 actuals compare

Brokerages including MOFSL, YES Securities, and JM Financial have projected ₹620 to ₹680 crore in revenue for Q4 FY26. The same set of projections puts PAT at ₹68 to ₹85 crore.

The article also provides Q3 actuals as reference points: Q3 revenue of ₹578 crore and Q3 PAT of ₹62 crore. That comparison matters because it frames what the Street expects as sequential improvement in both the top line and bottom line.

Stock price context: where Zydus Wellness is trading

Zydus Wellness was trading at ₹1,620 as of April 2026, according to the provided data. The stock’s 52-week high is ₹2,200 and the 52-week low is ₹1,380.

This range indicates the stock has seen material volatility over the past year. For many investors, results season acts as a catalyst to reassess whether current valuations reflect earnings momentum and the company’s ability to protect margins.

What the last reported Q4 (FY25) showed

The provided information includes details from a regulatory filing for a fourth quarter ended March 31, 2025. Consolidated total revenue from operations in that quarter stood at ₹910.6 crore, compared with ₹778 crore in the year-ago period.

Total expenses for that quarter were ₹740.5 crore, compared with ₹632.2 crore in the corresponding period a year earlier. In another data point for the same quarter, Zydus Wellness reported consolidated net profit of ₹171.9 crore, up 14.4% year-on-year, versus ₹150.3 crore.

The same set of details also mentions profit before tax (PBT) at ₹131.40 crore in the fourth quarter, down 0.95% from ₹132.66 crore.

Full-year FY25 profit trend and dividend reference

For FY25 (2024 to 2025), consolidated net profit was stated at ₹346.9 crore, compared with ₹266.9 crore in FY24 (2023 to 2024). The article also notes a proposal of a final dividend of ₹6 in the Q4 FY25 context.

These historical numbers are relevant mainly as a benchmark for how the company has performed in the immediate past and what investors may look for in payout commentary when the FY26 audited results are approved.

Additional financial snapshot cited in the data

The provided dataset also includes another set of quarterly metrics (period not specified in the source text). These figures cite revenue of ₹860.90 crore (down 5.72% QoQ from ₹913.10 crore) with YoY growth of 2.37%.

The same snapshot cites operating profit of ₹138.00 crore (up 22.12% QoQ from ₹113.00 crore) with YoY growth of 3.84%. It also cites PBDT of ₹28.20 crore (up 91.84% QoQ from ₹14.70 crore) with YoY growth of 213.33%, profit before tax of ₹145.30 crore (down 16.21% QoQ from ₹173.40 crore) with a YoY decline of 4.16%, and net profit of ₹127.90 crore (down 25.60% QoQ from ₹171.90 crore) with a YoY decline of 13.41%.

Key numbers snapshot (as provided)

Market impact: what to watch on result day

The immediate market reaction, if any, is typically driven by how reported numbers compare with the consensus ranges for revenue, PAT, and EBITDA margin. For Q4 FY26, the key comparison points provided are the revenue band of ₹620 to ₹680 crore, PAT of ₹68 to ₹85 crore, and EBITDA margin expectation of 16% to 18%.

Investors also track whether the board’s dividend recommendation aligns with past references, including the ₹6 final dividend proposal mentioned alongside Q4 FY25 details. In addition, commentary around audited consolidated and standalone numbers can influence perception, particularly when both quarterly and full-year results are approved together.

Company details provided

Registered Office: Zydus Corporate Park S No 536, Sarkhej-Gandhinagar Highway, Ahmedabad, Gujarat-382481. Phone: 91-79-67775888.

Conclusion

Zydus Wellness is expected to report Q4 FY26 results in May 2026, with the board set to approve audited quarterly and full-year numbers and consider a final dividend recommendation. Analysts are currently pencilling in ₹620 to ₹680 crore revenue, ₹68 to ₹85 crore PAT, and 16% to 18% EBITDA margin expectations, making the results a key near-term checkpoint for investors.